How to Cite
Abstract
Cancer stands out among the causes of death after heart disease. In the female population, ovarian cancer becomes more lethal than breast cancer, less than half of the women affected by the disease, live more than five years after the initial diagnosis. Most of the patients are diagnosed more frequently, after the menopause and in an advanced stage. The causes of the disease are associated with genetic and hormonal factors. Women who have symptoms related to ovarian cancer should undergo a physical examination, transvaginal ultrasound, and measurement of biomarkers such as cancer antigen 125. Once the diagnosis is made, patients should be referred to a gynecological oncologist, for the application of the corresponding treatment according to the stage of the disease.
Keywords
References
Cancer.org, Acerca del cáncer de ovario. [Sede Web]: cancer.org; 2020- [actualizada el 11 de abril de 2018; acceso 4 de septiembre de 2020]. Disponible en: https://www.contraceptionjournal.org/article/S0010-7824(17)30478-X/fulltext
cdc.gov, Health, United States, 2018: In Brief. [sede Web]: Hyattsville cdc.gov; 2020- [actualizada en 2019; acceso 4 de septiembre de 2020]. Disponible en: https://www.cdc.gov/nchs/hus/contents2018.htm
Brett R, Jennifer P, Thomas S. Epidemiology of ovarian cancer: a review. Cancer Biology & Medicine [revista en Internet] 2016 octubre [acceso 5 de septiembre de 2020] 14 (1). Disponible en: http://www.cancerbiomed.org/index.php/cocr/article/view/1004/1122
4. Del Campo J. Cáncer de Ovario. Sociedad Española de Oncología Médica SEOM [revista en Internet] 2020 enero [acceso 30 de octubre de 2020] 125 (8). Disponible en: https://seom.org/info-sobre-el-cancer/ovario
Alejandro C, Mario I, Amanda H, María G. Cáncer de Ovario: Tamizaje y diagnóstico Imagenológico. Med. leg. Costa Rica [revista en Internet] 2020 enero-marzo [acceso 4 de septiembre de 2020] 37 (1). Disponible en: https://www.scielo.sa.cr/scielo.php?script=sci_artext&pid=S1409-00152020000100054
Freddie B, Jacques F, Isabelle S, Rebecca L, Lindsey A, Ahmedin J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [revista en Internet] 2018 noviembre [acceso 4 de septiembre de 2020] 68 (6). Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492
Gaona R. El cáncer de ovario, el asalto del homicida invisible. Revista de la Facultad de Medicina de la UNAM [revista en Internet] 2014 enero - febrero [acceso 30 de octubre de 2020] 57 (1). Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422014000100004
Zhang L., Shin V. Y., Chai X., Zhang A., Chan T. L., Ma E. S., Rebbeck T. R., Chen J., Kwong A. Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women. Oncotarget. 2018; 9: 25025-25033. Disponible en: https://www.oncotarget.com/article/24382/text/
Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw 14, 9; https://doi.org/10.6004/jnccn.2016.0122
seer.cancer.gov, Oral Contraceptives and Cancer Risk. [sede Web]: seer.cancer.gov; 2020- [actualizada el 22 de febrero de 2018; acceso 4 de septiembre de 2020]. Disponible en: https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet
Zohre M, Azita T, Safoura T, Hamid S. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health [revista en Internet] 2019 abril [acceso 5 de septiembre de 2020] 11. Disponible en: https://www.researchgate.net/publication/332747210_Ovarian_cancer_in_the_world_epide miology_and_risk_factors
Oliva G, Nelson A, Carlos L. Comparación de tres índices ecográficos para evaluación del riesgo de malignidad de los tumores anexiales. Ginecol Obstet Mex [revista en Internet] 2018 agosto [acceso 5 de septiembre de 2020] 86 (8). Disponible en: http://www.scielo.org.mx/pdf/gom/v86n8/0300-9041-gom-86-08-519.pdf
Jacobs I. Steady, relentless progress towards effective, safe screening for early detection of cancer of the ovary. BJOG [revista en Internet] 2017 julio [acceso 5 de septiembre de 2020];14(2): Disponible en: https://obgyn.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1471-0528.14830
Daly MB, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. [revista en Internet] 2016 [acceso 5 de septiembre de 2020];14(2): Disponible en https://jnccn.org/view/journals/jnccn/14/2/article-p153.xml
Jacobs I, Menon U, Ryan A. Ovarian cancer screening and mortal-ity in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet [revista en Internet] 2016 marzo [acceso 5 de septiembre de 2020] 387. Disponible en: https://www.thelancet.com/journals/lancet/articlePIIS0140-6736(15)01224-6/fulltext
National Cancer Institute. [base de datos en Internet]. Surveillance, Epidemiology, and End Results Program. Statistical summaries: cancer stat fact sheets (ovary)
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women’s Health. 2019;(Volumen 11):287-299.
Doubeni. Diagnosis and Management of Ovarian Cancer. AAFP. 2016; 93(11):937-944.
Suppiah S. The Past, Present and Future of Diagnostic Imaging in Ovarian Cancer. Ovarian Cancer - From Pathogenesis to Treatment. 1st ed. Omer Devaja; 2018. p. 175-195.
Kang S, Reinhold C, Atri M, Benson C, Bhosale P, Jhingran A, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Ovarian Cancer. Journal of the American College of Radiology. 2018;15(5):S198-S207.
Suppiah S. The Past, Present and Future of Diagnostic Imaging in Ovarian Cancer. Ovarian Cancer - From Pathogenesis to Treatment. 1st ed. Omer Devaja; 2018. p. 175-195.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Array